Structure-Based analysis reveals cancer missense mutations target protein interaction interfaces

PLoS ONE

Volumn 11, Issue 4, 2016, Pages

  Engin, H Billur ^a   Kreisberg, Jason F ^a   Carter, Hannah ^a  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BETA 2 MICROGLOBULIN GENE; BINDING AFFINITY; BINDING SITE; CANCER SURVIVAL; CONTROLLED STUDY; GENETIC ANALYSIS; GENETIC SELECTION; HUMAN; HUMAN TISSUE; MISSENSE MUTATION; MUTATION RATE; OLIGOMERIZATION; ONCOGENE; PROTEIN DNA BINDING; PROTEIN NUCLEIC ACID INTERACTION; PROTEIN PROTEIN INTERACTION; PROTEIN RNA BINDING; PROTEIN STRUCTURE; STRUCTURE ANALYSIS; TP53 GENE; TUMOR GENE; TUMOR SUPPRESSOR GENE; BIOLOGY; CHEMISTRY; GENETIC DATABASE; GENETICS; METABOLISM; MOLECULAR MODEL; NEOPLASM; PROCEDURES; PROTEIN ANALYSIS; PROTEIN CONFORMATION; PROTEIN MULTIMERIZATION; STRUCTURE ACTIVITY RELATION;

MUTANT PROTEIN; PROTEIN BINDING; PROTEIN P53;

BINDING SITES; COMPUTATIONAL BIOLOGY; DATABASES, GENETIC; HUMANS; MODELS, MOLECULAR; MUTANT PROTEINS; MUTATION, MISSENSE; NEOPLASMS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN INTERACTION MAPPING; PROTEIN INTERACTION MAPS; PROTEIN MULTIMERIZATION; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84962795058     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0152929     Document Type: Article

References (57)

1. Jones S, Anagnostou V, Lytle K, Parpart-Li S, Nesselbush M, Riley DR, et al. Personalized genomic analyses for cancer mutation discovery and interpretation. Science translational medicine. 2015; 7 (283):283ra53. doi:10.1126/scitranslmed.aaa7161 PMID: 25877891.
2. Porta-Pardo E, Garcia-Alonso L, Hrabe T, Dopazo J, Godzik A. A Pan-Cancer Catalogue of Cancer Driver Protein Interaction Interfaces. PLoS computational biology. 2015; 11(10):e1004518. doi:10.1371/journal.pcbi.1004518 PMID: 26485003.
3. Zhong Q, Simonis N, Li QR, Charloteaux B, Heuze F, Klitgord N, et al. Edgetic perturbation models of human inherited disorders. Molecular systems biology. 2009; 5:321. doi:10.1038/msb.2009.80 PMID: 19888216.
4. Meyer MJ, Das J, Wang X, Yu H. INstruct: A database of high-quality 3D structurally resolved protein interactome networks. Bioinformatics. 2013; 29(12):1577-9. doi:10.1093/bioinformatics/btt181 PMID: 23599502.
5. Wang X, Wei X, Thijssen B, Das J, Lipkin SM, Yu H. Three-dimensional reconstruction of protein networks provides insight into human genetic disease. Nature biotechnology. 2012; 30(2):159-64. doi:10.1038/nbt.2106 PMID: 22252508.
6. David A, Razali R, Wass MN, Sternberg MJ. Protein-protein interaction sites are hot spots for diseaseassociated nonsynonymous SNPs. Human mutation. 2012; 33(2):359-63. doi:10.1002/humu.21656 PMID: 22072597.
7. Mosca R, Tenorio-Laranga J, Olivella R, Alcalde V, Ceol A, Soler-Lopez M, et al. dSysMap: Exploring the edgetic role of disease mutations. Nature methods. 2015; 12(3):167-8. doi:10.1038/nmeth.3289 PMID: 25719824.
8. Mosca R, Ceol A, Aloy P. Interactome3D: Adding structural details to protein networks. Nature methods. 2013; 10(1):47-53. doi:10.1038/nmeth.2289 PMID: 23399932.
9. Sahni N, Yi S, Taipale M, Fuxman Bass JI, Coulombe-Huntington J, Yang F, et al. Widespread macromolecular interaction perturbations in human genetic disorders. Cell. 2015; 161(3):647-60. doi:10.1016/j.cell.2015.04.013 PMID: 25910212.
10. Torkamani A, Schork NJ. Prediction of cancer driver mutations in protein kinases. Cancer research. 2008; 68(6):1675-82. doi:10.1158/0008-5472.CAN-07-5283 PMID: 18339846.
11. Shi Z, Moult J. Structural and functional impact of cancer-related missense somatic mutations. Journal of molecular biology. 2011; 413(2):495-512. doi:10.1016/j.jmb.2011.06.046 PMID: 21763698.
12. Vogelstein B, Papadopoulos N, Velculescu VE, Zhou S, Diaz LA Jr., Kinzler KW. Cancer genome landscapes. Science. 2013; 339(6127):1546-58. doi:10.1126/science.1235122 PMID: 23539594.
13. Yang F, Petsalaki E, Rolland T, Hill DE, Vidal M, Roth FP. Protein domain-level landscape of cancertype- specific somatic mutations. PLoS computational biology. 2015; 11(3):e1004147. doi:10.1371/journal.pcbi.1004147 PMID: 25794154.
14. Kamburov A, Lawrence MS, Polak P, Leshchiner I, Lage K, Golub TR, et al. Comprehensive assessment of cancer missense mutation clustering in protein structures. Proceedings of the National Academy of Sciences of the United States of America. 2015; 112(40):5486-95. doi:10.1073/pnas.1516373112 PMID: 26392535.
15. Miller Martin L. R E, Gauthier Nicholas P., Aksoy Bülent Arman, Korkut Anil, Gao Jianjiong, Ciriello Giovanni, Schultz Nikolaus, Sander Chris Pan-Cancer Analysis of Mutation Hotspots in Protein Domains. Cell Systems. 2015; 1(3):197-209.
16. Porta-Pardo E, Godzik A. E-Driver: A novel method to identify protein regions driving cancer. Bioinformatics. 2014; 30(21):3109-14. doi:10.1093/bioinformatics/btu499 PMID: 25064568.
17. Espinosa O, Mitsopoulos K, Hakas J, Pearl F, Zvelebil M. Deriving a mutation index of carcinogenicity using protein structure and protein interfaces. PloS one. 2014; 9(1):e84598. doi:10.1371/journal.pone.0084598 PMID: 24454733.
18. Vazquez M, Valencia A, Pons T. Structure-PPi: A module for the annotation of cancer-related singlenucleotide variants at protein-protein interfaces. Bioinformatics. 2015.
19. Engin HB, Guney E, Keskin O, Oliva B, Gursoy A. Integrating structure to protein-protein interaction networks that drive metastasis to brain and lung in breast cancer. PloS one. 2013; 8(11):e81035. doi:10.1371/journal.pone.0081035 PMID: 24278371.
20. Nishi H, Tyagi M, Teng S, Shoemaker BA, Hashimoto K, Alexov E, et al. Cancer missense mutations alter binding properties of proteins and their interaction networks. PloS one. 2013; 8(6):e66273. doi:10.1371/journal.pone.0066273 PMID: 23799087.
21. Engin HB, Hofree M, Carter H. Identifying mutation specific cancer pathways using a structurally resolved protein interaction network. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing. 2015:84-95. PMID: 25592571.
22. International Cancer Genome C, Hudson TJ, Anderson W, Artez A, Barker AD, Bell C, et al. International network of cancer genome projects. Nature. 2010; 464(7291):993-8. doi:10.1038/nature08987 PMID: 20393554.
23. Forbes SA, Beare D, Gunasekaran P, Leung K, Bindal N, Boutselakis H, et al. COSMIC: Exploring the world's knowledge of somatic mutations in human cancer. Nucleic acids research. 2015; 43(Database issue):805-11. doi:10.1093/nar/gku1075 PMID: 25355519.
24. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, et al. The Protein Data Bank. Nucleic acids research. 2000; 28(1):235-42. PMID: 10592235.
25. Pakula AA, Sauer RT. Genetic analysis of protein stability and function. Annual review of genetics. 1989; 23:289-310. PMID: 2694933.
26. Lawrence MS, Stojanov P, Polak P, Kryukov GV, Cibulskis K, Sivachenko A, et al. Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature. 2013; 499(7457):214-8. doi:10.1038/nature12213 PMID: 23770567.
27. Tamborero D, Gonzalez-Perez A, Lopez-Bigas N. Oncodrive CLUST: Exploiting the positional clustering of somatic mutations to identify cancer genes. Bioinformatics. 2013; 29(18):2238-44. doi:10.1093/bioinformatics/btt395 PMID: 23884480.
28. Greenman C, Stephens P, Smith R, Dalgliesh GL, Hunter C, Bignell G, et al. Patterns of somatic mutation in human cancer genomes. Nature. 2007; 446(7132):153-8. PMID: 17344846.
29. Carter H, Douville C, Stenson PD, Cooper DN, Karchin R. Identifying Mendelian disease genes with the variant effect scoring tool. BMC genomics. 2013; 14 Suppl 3:S3. doi:10.1186/1471-2164-14-S3-S3 PMID: 23819870.
30. Croft D, Mundo AF, Haw R, Milacic M, Weiser J, Wu G, et al. The Reactome pathway knowledgebase. Nucleic acids research. 2014; 42(Database issue):472-7. doi:10.1093/nar/gkt1102 PMID: 24243840.
31. Del Campo, AB, Kyte JA, Carretero J, Zinchencko S, Mendez R, Gonzalez-Aseguinolaza G, et al. Immune escape of cancer cells with beta2-microglobulin loss over the course of metastatic melanoma. International journal of cancer Journal international du cancer. 2014; 134(1):102-13. doi: 10.1002/ijc.28338 PMID: 23784959.
32. Freed-Pastor WA, Prives C. Mutant p53: one name, many proteins. Genes & development. 2012; 26 (12):1268-86.
33. Kohn KW. Molecular interaction map of the mammalian cell cycle control and DNA repair systems. Molecular biology of the cell. 1999; 10(8):2703-34. PMID: 10436023.
34. Chen K, Hu Z, Wang LE, Zhang W, El-Naggar AK, Sturgis EM, et al. Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. Clinical cancer research: An official journal of the American Association for Cancer Research. 2007; 13(14):4300- 5.
35. Chen D, Padiernos E, Ding F, Lossos IS, Lopez CD. Apoptosis-stimulating protein of p53-2 (ASPP2/53BP2L) is an E2F target gene. Cell death and differentiation. 2005; 12(4):358-68. PMID: 15592436.
36. Wang Y, Putnam CD, Kane MF, Zhang W, Edelmann L, Russell R, et al. Mutation in Rpa1 results in defective DNA double-strand break repair, chromosomal instability and cancer in mice. Nature genetics. 2005; 37(7):750-5. PMID: 15965476.
37. Kang R, Zhang Q, Zeh HJ 3rd, Lotze MT, Tang D. HMGB1 in cancer: good, bad, or both? Clinical cancer research: An official journal of the American Association for Cancer Research. 2013; 19(15):4046- 57.
38. Livesey KM, Kang R, Vernon P, Buchser W, Loughran P, Watkins SC, et al. p53/HMGB1 complexes regulate autophagy and apoptosis. Cancer research. 2012; 72(8):1996-2005. doi:10.1158/0008-5472.CAN-11-2291 PMID: 22345153.
39. Brosh R, Rotter V. When mutants gain new powers: news from the mutant p53 field. Nature reviews Cancer. 2009; 9(10):701-13. doi:10.1038/nrc2693 PMID: 19693097.
40. Poeta ML, Manola J, Goldwasser MA, Forastiere A, Benoit N, Califano JA, et al. TP53 mutations and survival in squamous-cell carcinoma of the head and neck. The New England journal of medicine. 2007; 357(25):2552-61. PMID: 18094376.
41. Seagle BL, Yang CP, Eng KH, Dandapani M, Odunsi-Akanji O, Goldberg GL, et al. TP53 hot spot mutations in ovarian cancer: Selective resistance to microtubule stabilizers in vitro and differential survival outcomes from The Cancer Genome Atlas. Gynecologic oncology. 2015.
42. Kitayner M, Rozenberg H, Kessler N, Rabinovich D, Shaulov L, Haran TE, et al. Structural basis of DNA recognition by p53 tetramers. Molecular cell. 2006; 22(6):741-53. PMID: 16793544.
43. Krissinel E, Henrick K. Inference of macromolecular assemblies from crystalline state. Journal of molecular biology. 2007; 372(3):774-97. PMID: 17681537.
44. Roadmap Epigenomics C, Kundaje A, Meuleman W, Ernst J, Bilenky M, Yen A, et al. Integrative analysis of 111 reference human epigenomes. Nature. 2015; 518(7539):317-30. doi:10.1038/nature14248 PMID: 25693563.
45. Robson S, Pelengaris S, Khan M. C-Myc and downstream targets in the pathogenesis and treatment of cancer. Recent patents on anti-cancer drug discovery. 2006; 1(3):305-26. PMID: 18221043.
46. Lawrence MS, Stojanov P, Mermel CH, Robinson JT, Garraway LA, Golub TR, et al. Discovery and saturation analysis of cancer genes across 21 tumour types. Nature. 2014; 505(7484):495-501. doi:10.1038/nature12912 PMID: 24390350.
47. Reimand J, Bader GD. Systematic analysis of somatic mutations in phosphorylation signaling predicts novel cancer drivers. Molecular systems biology. 2013; 9:637. doi:10.1038/msb.2012.68 PMID: 23340843.
48. Li S, Iakoucheva LM, Mooney SD, Radivojac P. Loss of post-translational modification sites in disease. Pacific Symposium on Biocomputing Pacific Symposium on Biocomputing. 2010:337-47. PMID: 19908386.
49. Humphrey W, Dalke A, Schulten K. VMD: visual molecular dynamics. Journal of molecular graphics. 1996; 14(1):33-8, 27-8. PMID: 8744570.
50. Hubbard SJT, J.M. NACCESS. Computer Program, Department of Biochemistry and Molecular Biology, University College London. 1993.
51. Martin AC. Mapping PDB chains to UniProtKB entries. Bioinformatics. 2005; 21(23):4297-301. PMID: 16188924.
52. Cingolani P, Platts A, Wang le L, Coon M, Nguyen T, Wang L, et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly. 2012; 6(2):80-92. doi:10.4161/fly.19695 PMID: 22728672.
53. Guerois R, Nielsen JE, Serrano L. Predicting changes in the stability of proteins and protein complexes: A study of more than 1000 mutations. Journal of molecular biology. 2002; 320(2):369-87. PMID: 12079393.
54. Cox DR O D. Analysis of Survival Data. New York: Chapman and Hall; 1987.
55. Therneau TM. A Package for Survival Analysis in S. 2.38 ed 2015.
56. Team RC. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing; 2013.
57. Greenman C, Wooster R, Futreal PA, Stratton MR, Easton DF. Statistical analysis of pathogenicity of somatic mutations in cancer. Genetics. 2006; 173(4):2187-98. PMID: 16783027.